Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer

NCT06682884 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Neoadjuvant Non-Small Cell Lung Cancer

Interventions

DRUG: Lorlatinib 100 mg

Sponsor

Peking University People's Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]